Home › Lung Cancer › NCT00280202

Detection of Genetic Markers of Lung Cancer

Detection of Genetic Markers of Lung Cancer Initiation and Progression

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Histologic confirmation of lung cancer, lung metastases from a primary site other than lung, mesothelioma or a radiographic lesion highly suspicious for malignancy
* Written informed consent.
* To be scheduled for a biopsy or surgical resection or have already had a biopsy and/or surgical removal of a lung mass

Exclusion Criteria:

None

About the study

The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.

What is being tested

• Biopsy of the major carinal area (procedure)
• Biopsy of abnormal & suspicious areas of the bronchial tree (procedure)
• Evaluation of the tumor for DNA mutations (procedure)
• Bronchoalveolar Lavage (BAL) for cytokine analysis (procedure)
• Correlation of flow cytometric & RT PCR for TNM stage (procedure)
• Analysis of lymph nodes (procedure)

Sponsor: University of Pittsburgh · Participants: 6,000 · Started: 1996-06

Contact the study team

• Arjun Pennathur, MD · Phone: 412-647-7555
• Julie Ward, BSN · Phone: 412-647-8583

Official record on ClinicalTrials.gov — NCT00280202

Locations in the U.S.

Conditions

• Lung Cancer

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.